Howard Weintraub, MD
Cardiovascular Disease · New York, NYNPI 1457347767
Payments from drug & device makers
Across 949 payments — averaging $1748.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$548K
- Novartis$325K
- Novo Nordisk AS$286K
- Eli Lilly$220K
- Novo Nordisk$192K
- Amarin Pharma, Inc.$23K
- plus $65K from 25 others
Across 3 payments — averaging $4949.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$12K
- Novartis$3K
What the payments were for
- Consulting fees$61,66619%
- Speaking & faculty fees$243,87474%
- Travel & lodging$6,8072%
- Food & beverage$15,5035%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 172 | $548,205 |
| Novartis | 111 | $324,944 |
| Novo Nordisk AS | 145 | $285,757 |
| Eli Lilly | 3 | $220,096 |
| Novo Nordisk | 97 | $192,369 |
| Amarin Pharma, Inc. | 41 | $23,150 |
| Akcea Therapeutics, Inc. | 2 | $20,841 |
| Esperion Therapeutics, Inc. | 33 | $15,014 |
| AstraZeneca | 57 | $11,282 |
| Lilly USA, LLC | 10 | $4,916 |
| Regeneron | 1 | $4,165 |
| Boehringer Ingelheim | 74 | $4,145 |
| Kowa Pharmaceuticals America, Inc. | 33 | $777 |
| Regeneron Healthcare Solutions, Inc. | 8 | $772 |
| Johnson & Johnson | 41 | $652 |
| Sanofi-aventis U.S. LLC | 19 | $412 |
| Pfizer | 17 | $342 |
| Bayer | 23 | $330 |
| Merck | 14 | $317 |
| Kiniksa Pharmaceuticals, Ltd. | 11 | $218 |
| Medicure Pharma Inc. | 1 | $189 |
| Vifor Pharma, Inc. | 12 | $129 |
| Boston Scientific | 6 | $124 |
| Arbor Pharmaceuticals, Inc. | 6 | $102 |
| Gilead | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Bardy Diagnostics, Inc. | 1 | $39 |
| Althera Pharmaceuticals LLC | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,659,481 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 167 | $195,779 |
| EliquisApixaban | 164 | $169,047 |
| JardianceEmpagliflozin | 89 | $103,460 |
| Praluent PenAlirocumab | 79 | $72,071 |
| OzempicSemaglutide | 39 | $55,161 |
| EntrestoSacubitril/Valsartan | 27 | $34,780 |
| VascepaIcosapent Ethyl | 43 | $32,272 |
| BrilintaTicagrelor | 31 | $21,977 |
| NexletolBempedoic Acid | 20 | $16,008 |
| Ezetimibe | 402 | $11,564 |
| Icosapent Ethyl | 33 | $10,889 |
| Eplerenone | 57 | $5,759 |
| Rosuvastatin Calcium | 349 | $4,975 |
| Atorvastatin Calcium | 369 | $3,886 |
| Metoprolol Succinate | 176 | $2,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $342 | $169,047164 claims |
| Boehringer IngelheimJardiance | $4,145 | $103,46089 claims |
| Novo NordiskOzempic | $192,369 | $55,16139 claims |
| NovartisEntresto | $324,944 | $34,78027 claims |
| AstraZenecaBrilinta | $11,282 | $21,97731 claims |
| Esperion Therapeutics, Inc.Nexletol | $15,014 | $16,00820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Anuradha Lala-TrindadeNew York$1.5M
- Cezar StaniloaeNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.